质量风险管理Quality Risk Management⟴11. Upside of Risk: Opportunity

文摘   2024-11-29 15:14   上海  


点击上方


 瑞士WS卫森医药咨询 

关注卫森

  文献探讨  
以下分享美国质量学会出版的《质量风险管理基础:有效的基于风险思维的实用方法 Foundations of quality risk management: A practical approach to effective risk-based thinking》(第1版)中的第11章《Upside of Risk: Opportunity 风险的正面:机遇》的中英文对照。
之后我们将定期更新分享后续章节内容,并分享临床研发领域的风险管理案例分析。
快速回顾➡️
第一章请看:质量风险管理Quality Risk Management⟴1. 风险管理简介
第二章请看:质量风险管理Quality Risk Management⟴2. 质量和风险管理
第三章请看:质量风险管理Quality Risk Management⟴3. 风险是什么?
第四章请看:质量风险管理Quality Risk Management⟴4. 基于风险的思维
第五章请看:质量风险管理Quality Risk Management⟴5. 基于风险的决策
第六章请看:质量风险管理Quality Risk Management⟴6. ISO 9001与风险管理
第七章请看:质量风险管理Quality Risk Management⟴7. 基本风险识别与分析
第八章请看:质量风险管理Quality Risk Management⟴8. Events and Consequences 事件与后果
第九章请看:质量风险管理Quality Risk Management⟴9. Risk Modification 风险修改
第十章请看:质量风险管理Quality Risk Management⟴10. The Stakeholder 利益相关者
本篇摘要

This chapter explores the concept of risk, focusing not only on its negative aspects but also on the opportunities that arise from uncertainty. By examining various definitions of risk, from ISO standards to practical applications, we highlight the importance of considering both the downside and the upside of risk. In particular, the chapter discusses how a balanced approach to risk management can enhance decision-making in both product development and broader organizational strategies. The concept of risk-benefit analysis is introduced, offering a framework for evaluating potential outcomes and their impact on objectives.

本章探讨风险的概念,不仅关注其负面方面,还强调了不确定性中可能出现的机遇(正面的风险)。通过审视不同的风险定义,从ISO标准到实际应用,本章突出考虑风险的负面与正面两方面的重要性。特别讨论平衡的风险管理方法如何在产品开发和更广泛的组织战略中促进决策。风险收益分析的概念可以引入为一种评估潜在结果及其对目标影响的框架。

Reference:
Moon, J. (2020). Upside of risk: Opportunity. In J. Moon, (Ed)., Foundations of quality risk management: A practical approach to effective risk-based thinking. (1st Ed., pp. 44-46). American Society for Quality, Quality Press.


 原文链接请"阅读原文“在浏览器新开页面

Experience without theory is blind, but theory without experience is mere intellectual play.

有经验而无学问,胜于有学问而无经验。

– Immanuel Kant


Upside of Risk: Opportunity 风险的正面:机遇

Looking at only the downside of risk is akin to considering a coin to have only one side. Table 11.1 reproduces the dictionary definitions of the term “risk.”

仅关注风险的负面,就如同认为硬币只有一面。表11.1展示了“风险”一词的字典定义。






There is certainly a negative connotation of the term “risk.” But let us dispel this falsehood early on. We saw a few definitions of risk in earlier chapters, some with broader scope than others. Let us contrast two standard definitions and discuss their implications. ISO 13485:2016 (Medical Devices - Quality Management Systems) defines risk as:

“风险”一词确实带有负面含义,但让我们尽早消除这种误解。在前几章中,我们看到了几个对风险的定义,其中一些范围较广。让我们对比两个标准定义并讨论其意义。ISO 13485:2016(医疗器械 - 质量管理体系)将风险定义为:

Combination of the probability of occurrence of harm and the severity of that harm.
危害发生的可能性和危害严重性的组合。

ISO 9000:2015 (Quality Management Systems - Fundamentals and Vocabulary), from which ISO 9001:2015 derives all terms and definitions, defines risk as:

ISO 9000:2015(质量管理体系 - 基础和术语)是ISO 9001:2015的术语和定义来源,它将风险定义为:

Effect of uncertainty.
不确定性的影响。

Note: An effect is a deviation from the expected - positive or negative.

注:影响是对预期的偏差 - 可能是正面的,也可能是负面的。

ISO 31000:2018 (Risk Management Guidelines) defines risk as:

ISO 31000:2018 (风险管理指南)定义风险为:

Effect of uncertainty on objectives.
不确定性对目标的影响。

Note: An effect is a deviation from the expected. It can be positive, negative, or both, and can address, create or result in opportunities and threats.

注:影响是对预期的偏差。它可以是正面的、负面的,或两者兼有,并且可以涉及、创造或导致机遇和威胁。

As we can see from the three separate definitions, the scope of risk and risk management went from negative to positive. So which definition is right? The answer is, all of them.

从这三个独立的定义中,我们可以看到风险和风险管理的范围从负面延伸到了正面。那么哪个定义是正确的呢?答案是,所有的定义都正确。







The context of the organization as detailed in the upcoming Chapters 14 and 16 really defines the context of risk management. In the first definition, the negative aspect of risk is stressed since, in the context of medical devices, it makes sense to consider every possible failure of the device in detail from a safety and reliability standpoint. This one-tailed approach to risk arms the user with single-mindedness and specificity of scope (i.e., confined to failure and safety). But here too, one may argue that addition or deletion of design features may be opportunities that may well benefit from a risk and failure assessment. One can also argue that if one considers opportunities or upsides of risk right at the beginning, a more beneficial device can be manufactured.

正如之后的第14章和第16章所详细描述的,组织的背景真正决定了风险管理的背景。在第一个定义中,强调了风险的负面方面,因为在医疗设备的背景下,从安全性和可靠性角度考虑设备的每一个可能故障是有意义的。这种单边的风险方法赋予使用者专注和明确的范围(即仅限于失败和安全)。但也可以争辩,设计特性的增减可能是机遇,完全可以通过风险和失败评估来加以利用。也可以认为,如果一开始就考虑到风险的机遇或正面方面,可以制造出更有益的设备







ISO 9001:2015 and ISO 31000:2018 are more universal standards that take the two-tailed approach to risk, which includes positive and negative aspects. The benefits of this approach are apparent in system-level, operational, strategic, and enterprise risk management. But when we get to the product, process, or service level, as the risks tend to become more and more specific, many practitioners find it difficult and at times redundant to incorporate the opportunity side.

ISO 9001:2015和ISO 31000:2018是更为通用的标准,采用双边风险方法,涵盖了正面和负面方面。这种方法在系统级、操作级、战略级和企业级的风险管理中展现了明显的优势。但当我们进入产品、过程或服务级别时,由于风险越来越具体,许多从业者发现很难在其中加入机会方面,有时甚至显得多余。







To simplify, let us define an event, which is full of uncertainty (i.e., full of risk), as follows:

为了简化,我们将具有不确定性的事件(即充满风险的事件)定义如下:

A risky event is an event whose occurrence is uncertain, but if it were to occur, it may have a negative or positive impact on the product, process, or system.
一个风险事件是一个发生不确定的事件,但如果发生,它可能对产品、过程或系统产生负面或正面影响。

This risky event may be turning a screw in a spinal implant or choosing a new indication for a drug or adding a new navigation feature to a car. A potential failure mode is still a risk event but only with negative risk.

这个风险事件可能是转动脊柱植入物上的螺丝,选择药物的新适应症,或者为汽车增加新导航功能。一个潜在的失败模式仍然是一个风险事件,但只有负面风险。







Let us now look at an example that clarifies the concepts above related to risk, uncertainty, and positive and negative aspects. Let us consider a game where the correct guess on the outcome of a fair coin toss doubles your wager. We are aware that a fair coin toss has 50% probability of heads or tails. So here, the risky event is the coin toss, with a two-tailed risk.

现在让我们看一个例子,阐明上述关于风险、不确定性以及正面和负面方面的概念。我们来考虑一个游戏,在这个游戏中,正确猜测公平掷硬币的结果可以让你的赌注翻倍。我们知道公平的硬币投掷正反面概率各为50%。所以这里风险事件就是投掷硬币,具有双边风险。

If I flip a coin on a $5 wager and call heads, tails brings a 50% possibility of loss and financial injury to me, but heads brings a 50% possibility of profit for me. I could have chosen not to place the wager and not take a risk, but I decided that there was an opportunity for me to benefit by taking that risk. When such situations present themselves, how do you decide which path to take? Is the risk worth it?

如果在5美元的赌注上投掷硬币并猜正面,那么反面带来的50%的可能性是我会亏损并遭受经济损失,而正面则带来50%的可能性让我获得利润。我本可以选择不下注,避免冒险,但我决定通过承担这个风险来获取潜在的收益。当这种情况出现时,你会如何决定选择哪条路?这个风险值得吗?







A risk-benefit analysis can help drive a decision in such cases. Below is one that I performed on the fly for this simple two-outcome event by doing the following:

在这种情况下,风险收益分析可以帮助做出决策。下面是针对这个简单的两种结果事件快速进行的分析,方法如下:

Assigning probability to the positive outcome 为正面结果分配概率
Assigning impact level to the positive outcome 为正面结果分配影响等级
Assigning probability to the negative outcome 为负面结果分配概率
Assigning impact level to the negative outcome 为负面结果分配影响等级
Comparing total risk between the two outcomes by using a risk equation 使用风险方程比较两种结果的总风险

Table 11.2 shows the tabulated risk-benefit analysis.

表11.2显示了整理出的风险收益分析。








Table 11.2, in fact, is known as expected monetary value analysis (commonly used in project management) and is often used to quantify aggregate risk by multiplying the likelihood of the outcome by the impact of the outcome. This multiplicative product gives an expected monetary value for each outcome, which can be added across all outcomes to give a final level of risk. The aggregate expected output here is $2.50, which does not mean I will earn $2.50 but if I play this game over and over again multiple times, I will probably end up with an average gain of $2.50.

事实上,表11.2被称为预期货币价值分析(在项目管理中常用),它通常用于通过将结果的可能性与结果的影响相乘来量化总风险。这个乘积给出了每种结果的期望货币价值,可以将所有结果加总,得出最终的风险水平。这里的总期望输出为2.50美元,这并不意味着我会赚到2.50美元,但如果我多次玩这个游戏,我可能最终会得到2.50美元的平均收益。

So, the question I need to answer in this simple risk-benefit analysis is: Am I fine with the expected monetary value of $2.50? or Am I fine with a 50% chance of losing $5 for a 50% chance to gain $10?

所以,我在这个简单的风险收益分析中需要回答的问题是:我接受2.50美元的期望货币价值吗?还是我接受50%的概率亏损5美元,换取50%概率获得10美元?







The key concept here is that risk is involved for all outcomes borne out of uncertainty. Some of these outcomes are beneficial and have a positive risk or an opportunity associated with them. Risk-benefit analysis is mentioned in detail in the upcoming Chapter 36.

这里的关键概念是,所有结果都来源于不确定性,因此都涉及风险。这些结果中的一些是有益的,并且与正面风险或机遇相关。风险收益分析将在之后的第36章中详细介绍。







Get in touch and

meet our team!

WS卫森医药咨询(上海)有限公司
创建于瑞士;专家顾问团队布局德国、美国、中国,在医药行业或国际监管机构组织有平均20年的多元专业领域经验;擅长临床研发到商业化的GxP全过程战略构建、技术咨询与互动式培训,致力为国内外医药生技公司定制合规国际标准的质量及风险体系,並助力推动跨部门高效实践 
欢迎回复公众号| 联系卫森中国团队

往期回顾 Featured Articles


☑️药物研发全过程战略咨询
 佈局海外-药企进军欧美市场的战略规划(一)
 Integrated Support Throughout Your Drug Development Value Chain
 临床研究监查稽查检查实操问题解惑12345678┊9
 FDA新药开发会议-WS卫森医药咨询主管合伙人彼得·希曼博士的两项倡议
 WS卫森医药咨询亚太区首席顾问赵筠之:综观医药行业发展的趋势和提醒
 WS德国分公司新成立及国际团队加入新阵容
 欢迎Martin E. Zuzulo加入WS卫森医药咨询美国分公司团队
 欢迎GCP稽查专家Władysław Kalin加入WS卫森医药咨询德国分公司团队
 风险管理攻略(一)研发项目及临床试验的风险管理
 风险管理攻略(二)PEST分析模型
 风险管理攻略(三)FEMA失效模式与影响分析
 风险管理攻略(四)风险评估与战略性稽查计划
 风险管理攻略(五)RACI分工模型表
 药物开发全过程质量管理-高阶流程图
 中美新药临床试验申请概览China & US IND Overview
 中国VS欧洲新药临床试验申请概览China & Europe IND/CTA Overview
 直播课:确保中国申办方在美国CDMO领域的质量监管|WS卫森医药咨询美国分公司负责人Marty Zuzulo老师
 WS顾问服务┆FDA/EMA Inspection Readiness 美国/欧盟药监检查准备
☑️国际监管动态
 盘点国际医药政策 2020 JAN-1┊-2┊FEB-1┊-2┊-3┊MAR-1┊-2APR-1┊-2┊MAY┊JUN-1┊-2┊JUL-1-2┊AUG┊SEP-1-2┊OCT-1┊-2┊-3┊-4┊NOV┊DEC-1┊-2┊2021 JAN┊FEB -1┊-2┊MAR-1┊-2┊APR-1┊-2┊MAY-1┊-2┊JUN-1┊-2┊JUL-1┊-2┊AUG┊SEP-1┊-2┊OCT-1┊-2┊NOV-1┊-2┊-3┊DEC-1┊-2-3┊2022 JAN-1┊
FEB-1┊MAR-1┊MAR-2┊MAR-3┊APR-1┊APR-2┊MAY-1┊JUN-1┊-2┊JUL┊SEP┊OCTDEC┊2023 JAN-1-2FEBMARAPRMAYJUNJUL┊DEC┊2024 FEB
 世界各国临床研究标准汇编2020版
 详解┊欧盟药监局2020年度报告
 详解┊欧盟药监局2019年药品审批报告
欧盟药监药物不良反应系统年度报告EMA 2021 Annual EudraVigilance Report
欧盟药监检查记录常见问题指南EMA FAQs Guidance on Inspection Records
 欧盟药监GMP/GDP检查员工作组2021年度报告 EMA 2021 GMP/GDP IWG Annual Report
 欧盟药监GCP工作组2018年度GCP工作总结暨Inspection汇总报告
 欧盟药监GCP检查年度报告EMA GCP Inspectors Working Group Annual Report
 欧盟药监PV工作组2018年度PV工作总结暨Inspection汇总报告
 欧盟药监《DMC数据监查委员会》官方问与答(1)(2)
 欧盟药监《寻求科学建议和方案支持的申请者指南》官方问与答(7/7)
 欧盟药监EMA Inspection工作组GCP Q&A(1)(2)(3)(4)(5)
 英国药监MHRA《回复MHRA对GLP及GCP实验室的检查报告》指南
 英国药监MHRA 2019 GVP Inspection年度报告
 英国药监MHRA 2019 GCP Inspection年度报告
 英国药监MHRA 2020 GCP Inspection年度报告
 英国药监MHRA 2020 GVP Inspection 年度报告
 澳洲药监TGA发布2019年度PV检查汇总报告
 TGA PV Inspection Program Risk Assessment Survey
 欧盟官宣!第1000次GCP Inspection
 FDA近五年临床试验信息汇总(1/2)(2/2)
 FDA生物研究监查项目(BIMO)数据分析
 FDA基于风险的监查(RBM)更新指南Q&A
 FDA药审中心(CDER)药品生命周期安全性数据管理
 FDA加强全球性药品检查项目以确保仿制药安全性
 FDA+MHRA: QMS & QbD
 FDA+MHRA: GCP检查程序类型及联合检查合作模式
 FDA的GCP检查案例分析-对稽查轨迹的审核思维
 TMF Reference Model V3.3.1
 ICH E6(R2)VS(R3)-Risk Management 比较药物临床研究质量管理规范中对于风险管理的更新要求
 法规解读⟴FDA更新版指南《临床研究中的电子系统、电子记录和电子签名:问与答》
☑️药物研发质量管理与风险管理

 质量管理体系,魔鬼藏在细节里!

 从ICH Q10浅谈药品质量体系
 Quality by Design (QbD) 质量源于设计
 Kaizen!今天你进步了吗?
 受控文件管理好,临床试验才可靠
 建多少不如建得巧的质量体系
 质量体系初始培训
 药物警戒初级培训┊进阶培训
 独立数据监察委员会(一)┊(二)┊(三)┊(四) 
 欧盟药监《DMC数据监查委员会》官方问与答(1)(2)
 临床试验的现场启动考察(SIV)要点
 面对来自监管机构检查的准备及工作要点(一)
 文献探讨⟴综合评估临床试验中基于风险的质量管理
 文献探讨⟴改善临床试验质量:DIA对RBQM基于风险的质量管理的行业调查与见解
 质量风险管理Quality Risk Management⟴1.风险管理简介
 质量风险管理Quality Risk Management⟴2. 质量和风险管理
 质量风险管理Quality Risk Management⟴3. 风险是什么?
 质量风险管理Quality Risk Management⟴4. Risk-Based Thinking 基于风险的思维
 质量风险管理Quality Risk Management⟴5. 基于风险的决策
 质量风险管理Quality Risk Management⟴6. ISO 9001与风险管理
 质量风险管理Quality Risk Management⟴7. 基本风险识别与分析
 质量风险管理Quality Risk Management⟴8. Events and Consequences 事件与后果
 质量风险管理Quality Risk Management⟴9. Risk Modification 风险修改

瑞士WS卫森医药咨询
✔创于瑞士,在中国、美国、德国设有分公司,已累积为全球七十多家医药企业提供定制化质量管理体系解决方案✔专长GxP(GCP/GMP/GLP/GSP) 质量管理体系全程技术咨询、建设与培训✔顾问团队在业界/国际监管机构组织有平均20年多元经验
 最新文章